Dual CAR T-cell therapy enables high-risk kidney transplants in breakthrough trial

A groundbreaking clinical trial has allowed two patients with severe kidney disease to receive life-saving transplants. For years, their high levels of immune antibodies made finding a compatible donor nearly impossible. Now, a new therapy has changed that outcome. The trial, published in the New England Journal of Medicine, marks the first use of dual CAR T-cell therapy to target immune cells producing anti-donor antibodies. These harmful antibodies had left the patients—including 47-year-old Andrew Boyd from Philadelphia—highly sensitised and unable to accept most donor kidneys.

Boyd, who had already undergone two previous transplants, saw his antibody levels drop sharply within weeks of receiving the engineered immune cells. This reduction allowed doctors to find a suitable kidney match, leading to his third successful transplant. Around 5,000 people in the U.S. face similar challenges, waiting for transplants while their immune systems reject potential donors. This Phase I trial is the first to show that CAR T-cell therapy can remove the specific immune cells blocking these critical procedures.

The results offer a new path for patients previously deemed too high-risk for transplants. With further testing, this approach could expand treatment options for thousands awaiting kidneys. The study’s success also opens doors for broader applications of CAR T-cell therapy in transplantation medicine.